Eli Lilly's Q2 Sales Surge 36%, Analysts Cautious On Future Supply, Market Dynamics; Optimistic About Next-Gen Oral Weight-Loss Drug

Eli Lilly And Co LLY reported on Thursday second-quarter revenue of $11.3 billion, up 36% year-over-year, easily surpassing the consensus of $9.95 billion.Mounjaro sales tripled to $3.09 billion from $979.7 million a year ago. Zepbound sales reached $1.24 billion, up from $517.4 million reported in the first quarter of 2024 since it received FDA approval in November 2023.Goldman Sachs noted that Eli Lilly’s second-quarter performance benefited from better channel dynamics and clearer manufacturing processes ...